CN114728189A - 抗癌剂暴露防止方法 - Google Patents
抗癌剂暴露防止方法 Download PDFInfo
- Publication number
- CN114728189A CN114728189A CN202080078466.7A CN202080078466A CN114728189A CN 114728189 A CN114728189 A CN 114728189A CN 202080078466 A CN202080078466 A CN 202080078466A CN 114728189 A CN114728189 A CN 114728189A
- Authority
- CN
- China
- Prior art keywords
- hypochlorous acid
- solution
- anticancer agent
- aqueous solution
- test
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 70
- 238000000034 method Methods 0.000 title claims abstract description 27
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 claims abstract description 64
- 239000007864 aqueous solution Substances 0.000 claims abstract description 58
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims abstract description 30
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims abstract description 22
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229960004397 cyclophosphamide Drugs 0.000 claims abstract description 16
- 229930012538 Paclitaxel Natural products 0.000 claims abstract description 15
- 229960001592 paclitaxel Drugs 0.000 claims abstract description 15
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims abstract description 15
- 229960004679 doxorubicin Drugs 0.000 claims abstract description 13
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims abstract description 11
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229960002707 bendamustine Drugs 0.000 claims abstract description 11
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims abstract description 11
- 229960004316 cisplatin Drugs 0.000 claims abstract description 11
- 229960002949 fluorouracil Drugs 0.000 claims abstract description 11
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims abstract description 11
- 229960005277 gemcitabine Drugs 0.000 claims abstract description 11
- 229960001428 mercaptopurine Drugs 0.000 claims abstract description 11
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims abstract description 11
- 229960001756 oxaliplatin Drugs 0.000 claims abstract description 11
- 229960004528 vincristine Drugs 0.000 claims abstract description 11
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims abstract description 11
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000000243 solution Substances 0.000 claims description 66
- 238000005507 spraying Methods 0.000 claims description 18
- 239000006199 nebulizer Substances 0.000 claims 1
- 238000012360 testing method Methods 0.000 description 67
- 238000000354 decomposition reaction Methods 0.000 description 51
- 239000007788 liquid Substances 0.000 description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- 239000000126 substance Substances 0.000 description 19
- 238000002360 preparation method Methods 0.000 description 18
- 239000003814 drug Substances 0.000 description 16
- 239000008213 purified water Substances 0.000 description 16
- 229940079593 drug Drugs 0.000 description 13
- 238000005259 measurement Methods 0.000 description 13
- 239000011550 stock solution Substances 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 11
- 238000010998 test method Methods 0.000 description 10
- 229940041181 antineoplastic drug Drugs 0.000 description 9
- 238000012790 confirmation Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 239000012488 sample solution Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 7
- 239000005708 Sodium hypochlorite Substances 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 230000003472 neutralizing effect Effects 0.000 description 6
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 5
- 238000011835 investigation Methods 0.000 description 5
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 229940100198 alkylating agent Drugs 0.000 description 4
- 239000002168 alkylating agent Substances 0.000 description 4
- 239000003595 mist Substances 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229940009456 adriamycin Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003560 cancer drug Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 206010073310 Occupational exposures Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960001566 methyltestosterone Drugs 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007524 negative regulation of DNA replication Effects 0.000 description 1
- 230000021616 negative regulation of cell division Effects 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 231100000675 occupational exposure Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 239000011882 ultra-fine particle Substances 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A62—LIFE-SAVING; FIRE-FIGHTING
- A62D—CHEMICAL MEANS FOR EXTINGUISHING FIRES OR FOR COMBATING OR PROTECTING AGAINST HARMFUL CHEMICAL AGENTS; CHEMICAL MATERIALS FOR USE IN BREATHING APPARATUS
- A62D3/00—Processes for making harmful chemical substances harmless or less harmful, by effecting a chemical change in the substances
- A62D3/30—Processes for making harmful chemical substances harmless or less harmful, by effecting a chemical change in the substances by reacting with chemical agents
- A62D3/38—Processes for making harmful chemical substances harmless or less harmful, by effecting a chemical change in the substances by reacting with chemical agents by oxidation; by combustion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L9/00—Disinfection, sterilisation or deodorisation of air
- A61L9/01—Deodorant compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L9/00—Disinfection, sterilisation or deodorisation of air
- A61L9/14—Disinfection, sterilisation or deodorisation of air using sprayed or atomised substances including air-liquid contact processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2101/00—Chemical composition of materials used in disinfecting, sterilising or deodorising
- A61L2101/02—Inorganic materials
- A61L2101/06—Inorganic materials containing halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2209/00—Aspects relating to disinfection, sterilisation or deodorisation of air
- A61L2209/10—Apparatus features
- A61L2209/13—Dispensing or storing means for active compounds
- A61L2209/132—Piezo or ultrasonic elements for dispensing
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Emergency Management (AREA)
- Business, Economics & Management (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019203722 | 2019-11-11 | ||
| JP2019-203722 | 2019-11-11 | ||
| PCT/JP2020/041778 WO2021095696A1 (ja) | 2019-11-11 | 2020-11-09 | 抗がん剤曝露防止方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114728189A true CN114728189A (zh) | 2022-07-08 |
Family
ID=75912915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080078466.7A Pending CN114728189A (zh) | 2019-11-11 | 2020-11-09 | 抗癌剂暴露防止方法 |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JPWO2021095696A1 (enrdf_load_stackoverflow) |
| KR (1) | KR20220084109A (enrdf_load_stackoverflow) |
| CN (1) | CN114728189A (enrdf_load_stackoverflow) |
| TW (1) | TW202123978A (enrdf_load_stackoverflow) |
| WO (1) | WO2021095696A1 (enrdf_load_stackoverflow) |
Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1134670A (zh) * | 1993-11-12 | 1996-10-30 | 纽卡斯尔大学文图拉有限公司 | 亚甲兰用于治疗或预防异环磷酰胺引起的脑病 |
| CN1285838A (zh) * | 1997-11-11 | 2001-02-28 | 宝酒造株式会社 | 利用来源于藻类的生理活性物质的药物、食品或饮料 |
| JP2003169842A (ja) * | 2001-12-04 | 2003-06-17 | Sony Corp | 次亜塩素酸水溶液による殺菌方法および殺菌装置 |
| WO2003082216A2 (en) * | 2002-03-28 | 2003-10-09 | Oxis International, Inc. | Neuroprotectant methods, compositions, and screening methods thereof |
| JP2006081802A (ja) * | 2004-09-17 | 2006-03-30 | Technomax:Kk | 次亜塩素酸含有水による悪臭物質収容施設の殺菌・消臭方法及びそれに用いる装置 |
| TW200714276A (en) * | 2005-10-12 | 2007-04-16 | Chiayi University | Method for producing anti-tumor compound, piceatannol |
| JP3166522U (ja) * | 2010-12-24 | 2011-03-10 | ナナイロ株式会社 | 除菌消臭用噴霧器 |
| JP2012091114A (ja) * | 2010-10-27 | 2012-05-17 | Iwate Medical Univ | 光触媒水性組成物及び該組成物を用いた抗がん剤分解法 |
| CN102480972A (zh) * | 2009-06-15 | 2012-05-30 | 奥古露丝创新科学公司 | 含有次氯酸的溶液及其使用方法 |
| CN102939130A (zh) * | 2010-04-14 | 2013-02-20 | 海波流动有限公司 | 制备稀释消毒剂溶液的设备 |
| CN105246554A (zh) * | 2013-06-25 | 2016-01-13 | 株式会社田村特科 | 抗癌剂分解方法及抗癌剂分解装置 |
| US20180140549A1 (en) * | 2015-06-09 | 2018-05-24 | Sun Pharma Advanced Research Company Ltd | Method of treating carcinoma |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS53125312A (en) | 1977-04-07 | 1978-11-01 | Kajima Corp | Method of placing underground wall |
| US6092445A (en) | 1999-04-29 | 2000-07-25 | Skackelford; Jerry Lynn | Telescoping die holder |
| JP6258600B2 (ja) | 2013-05-08 | 2018-01-10 | ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎ Ａｎｄ Ｃｏｍｐａｎｙ | 輸液チューブセットおよびその使用方法 |
| JP7175766B2 (ja) | 2016-03-28 | 2022-11-21 | アプライド マテリアルズ インコーポレイテッド | サセプタ支持体 |
| KR102329676B1 (ko) | 2017-05-17 | 2021-11-19 | 엘지전자 주식회사 | 스마트 비데 및 이를 포함하는 제어 시스템 |
| JP2020174900A (ja) * | 2019-04-18 | 2020-10-29 | 緒方 康夫 | 抗癌剤を分解するための薬剤および方法 |
-
2020
- 2020-11-09 KR KR1020227016126A patent/KR20220084109A/ko not_active Ceased
- 2020-11-09 WO PCT/JP2020/041778 patent/WO2021095696A1/ja not_active Application Discontinuation
- 2020-11-09 CN CN202080078466.7A patent/CN114728189A/zh active Pending
- 2020-11-09 JP JP2021556088A patent/JPWO2021095696A1/ja active Pending
- 2020-11-10 TW TW109139151A patent/TW202123978A/zh unknown
Patent Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1134670A (zh) * | 1993-11-12 | 1996-10-30 | 纽卡斯尔大学文图拉有限公司 | 亚甲兰用于治疗或预防异环磷酰胺引起的脑病 |
| CN1285838A (zh) * | 1997-11-11 | 2001-02-28 | 宝酒造株式会社 | 利用来源于藻类的生理活性物质的药物、食品或饮料 |
| JP2003169842A (ja) * | 2001-12-04 | 2003-06-17 | Sony Corp | 次亜塩素酸水溶液による殺菌方法および殺菌装置 |
| WO2003082216A2 (en) * | 2002-03-28 | 2003-10-09 | Oxis International, Inc. | Neuroprotectant methods, compositions, and screening methods thereof |
| JP2006081802A (ja) * | 2004-09-17 | 2006-03-30 | Technomax:Kk | 次亜塩素酸含有水による悪臭物質収容施設の殺菌・消臭方法及びそれに用いる装置 |
| TW200714276A (en) * | 2005-10-12 | 2007-04-16 | Chiayi University | Method for producing anti-tumor compound, piceatannol |
| CN102480972A (zh) * | 2009-06-15 | 2012-05-30 | 奥古露丝创新科学公司 | 含有次氯酸的溶液及其使用方法 |
| CN102939130A (zh) * | 2010-04-14 | 2013-02-20 | 海波流动有限公司 | 制备稀释消毒剂溶液的设备 |
| JP2012091114A (ja) * | 2010-10-27 | 2012-05-17 | Iwate Medical Univ | 光触媒水性組成物及び該組成物を用いた抗がん剤分解法 |
| JP3166522U (ja) * | 2010-12-24 | 2011-03-10 | ナナイロ株式会社 | 除菌消臭用噴霧器 |
| CN105246554A (zh) * | 2013-06-25 | 2016-01-13 | 株式会社田村特科 | 抗癌剂分解方法及抗癌剂分解装置 |
| EP3015137A1 (en) * | 2013-06-25 | 2016-05-04 | Tamura Teco Co. Ltd. | Anticancer agent decomposition method and anticancer agent decomposition device |
| US20180140549A1 (en) * | 2015-06-09 | 2018-05-24 | Sun Pharma Advanced Research Company Ltd | Method of treating carcinoma |
Non-Patent Citations (2)
| Title |
|---|
| 刘华之等: "《医院感染预防与控制研究》", 31 March 2019, 吉林大学出版社 * |
| 川地晶子等: "分包調剤作業時に飛散した「ロイケリン散10%」の簡便安全清掃处理法", 《医学薬学》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220084109A (ko) | 2022-06-21 |
| WO2021095696A1 (ja) | 2021-05-20 |
| JPWO2021095696A1 (enrdf_load_stackoverflow) | 2021-05-20 |
| TW202123978A (zh) | 2021-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | Nanocatalytic biofunctional MOF coating on titanium implants promotes osteoporotic bone regeneration through cooperative pro-osteoblastogenesis MSC reprogramming | |
| CA2765696C (en) | Solution containing hypochlorous acid and methods of using same | |
| US20040086453A1 (en) | Compositions, methods, apparatuses, and systems for singlet oxygen delivery | |
| JP5475765B2 (ja) | ガスミスト吸入器 | |
| KR20070113315A (ko) | 산화 환원 전위 수용액을 사용한 2도 및 3도 화상의 치료방법 | |
| DE102005035472A1 (de) | Chemische Dialysatformulierungen auf Citratbasis | |
| TWI601542B (zh) | 一種用於治療肺癌之吸入式醫藥組成物及其備製方法 | |
| TW201039835A (en) | Chlorine dioxide treatment for biological tissue | |
| TWI658866B (zh) | 氣體產生器 | |
| CN114728189A (zh) | 抗癌剂暴露防止方法 | |
| JP2020174900A (ja) | 抗癌剤を分解するための薬剤および方法 | |
| US20020098246A1 (en) | Compositions, methods, apparatuses, and systems for singlet oxygen delivery | |
| US20110077572A1 (en) | Medical Equipment and Products using Chlorine, Hydrogen Peroxide, and Anti-Viral, Anti-Bacterial, Anti-Fungal, Agents, usage Method Improvements Dread Disease Cures, Remissions, and Anti-Infective Treatment Measures, Disease Treatment and Prevention System | |
| US20040009964A1 (en) | Compositions and methods for the treatment of matrix metalloproteinase-related diseases | |
| JP2024090489A (ja) | 抗がん剤分解液 | |
| JP2024064799A (ja) | 抗がん剤分解液及びこれを用いた抗がん剤分解方法 | |
| JP7012065B2 (ja) | 即効性抗がん剤分解剤及び即効性抗がん剤分解方法 | |
| RU2656198C2 (ru) | Маска медицинская антибактериальная, способ ее изготовления и способ применения | |
| EP3534809B1 (de) | Débridement-vorrichtung | |
| EP1353679A2 (en) | Compositions, methods and apparatuses for singlet oxygen delivery | |
| CN100384435C (zh) | 一种治疗鼻腔疾病的盐水药液及应用装置 | |
| CN103920237B (zh) | 一种修复dna氧化损害的装置 | |
| JP2021179024A (ja) | 薬剤分解シート及びこの薬剤分解シートを用いた製品 | |
| TR202011127Y (tr) | Hi̇pokloröz asi̇t üreti̇m ci̇hazi | |
| Dobson | Chemotherapy Protocols and Safety |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20220708 |
|
| WD01 | Invention patent application deemed withdrawn after publication |